Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
1,2000
Trial Sponsor
Clinical Trial Start Date
December 2, 2024
0Primary Completion Date
May 23, 2025
0Study Completion Date
May 23, 2025
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Intervention Type
Biological0
Interventional Trial Phase
Phase 30
Phase 20
Official Name
A Phase 3, Randomized, Observer-Blinded, Study to Compare the Safety and Immunogenicity of 3 Lots of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine With Matrix M™ Adjuvant in Participants ≥ 60 Years of Age0
Last Updated
July 3, 2024
0Allocation Type
Randomized0
Intervention Model
Crossover Assignment0
Masking Type
Single0
Masked Party
Participant0
Other attributes
Intervention Treatment
tNIV 1 and Matrix-M Adjuvant0
Study summary
Phase 3 Study Comparing Safety and Immune Response of Three Batches of Novavax Flu Vaccine in older adult participants
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
